The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
about
EGFR-targeted therapies in the post-genomic era.TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.Leveraging Genomics for Head and Neck Cancer Treatment.Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Role, Controversy, and Future Directions.
P2860
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The KRAS-Variant and Cetuximab ...... f a Randomized Clinical Trial.
@en
type
label
The KRAS-Variant and Cetuximab ...... f a Randomized Clinical Trial.
@en
prefLabel
The KRAS-Variant and Cetuximab ...... f a Randomized Clinical Trial.
@en
P2093
P2860
P1433
P1476
The KRAS-Variant and Cetuximab ...... f a Randomized Clinical Trial.
@en
P2093
Adel K El-Naggar
Allen M Chen
Andy Trotti
Anurag K Singh
Chance Matthiesen
Christine H Chung
David Raben
David Sidransky
Dörthe Schaue
P2860
P304
P356
10.1001/JAMAONCOL.2016.5478
P577
2016-12-22T00:00:00Z